ADC Therapeutics Announces Preliminary 2025 Financial Results and Outlook

ADC Therapeutics ( (ADCT) ) has provided an update.

On January 8, 2026, ADC Therapeutics reported preliminary, unaudited 2025 financial figures indicating ZYNLONTA net product revenue of about $73 million for the full year, up modestly from $69.3 million in 2024, and approximately $22 million in the fourth quarter versus $16.4 million a year earlier, with demand in its current third-line-plus DLBCL indication described as broadly stable and cash and cash equivalents of roughly $261 million expected to fund operations at least to 2028. Operationally, the company highlighted strong updated Phase 1b LOTIS-7 data released in December 2025 for ZYNLONTA in combination with glofitamab in relapsed or refractory DLBCL, outlined key upcoming clinical milestones including expected topline Phase 3 LOTIS-5 results in second-quarter 2026 and full LOTIS-5 and LOTIS-7 data by the end of 2026, reported promising early results from investigator-initiated trials in indolent lymphomas, and noted completion of IND-enabling work on a PSMA-targeting ADC, all of which position the company for potential future label expansions and revenue acceleration but leave near-term growth still reliant on its existing ZYNLONTA franchise and successful execution of its clinical and regulatory strategy.

The most recent analyst rating on (ADCT) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on ADC Therapeutics stock, see the ADCT Stock Forecast page.

Spark’s Take on ADCT Stock

According to Spark, TipRanks’ AI Analyst, ADCT is a Neutral.

ADC Therapeutics’ overall stock score is primarily impacted by its financial instability, with persistent losses and negative equity. While technical analysis and valuation suggest caution, the earnings call and corporate events provide some optimism with promising clinical results and strategic financial moves.

To see Spark’s full report on ADCT stock, click here.

More about ADC Therapeutics

ADC Therapeutics SA is a commercial-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs), led by its CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior lines of systemic therapy. Headquartered in Lausanne, Switzerland, with operations in London and New Jersey, the company focuses on developing and commercializing ADC-based oncology treatments and advancing ZYNLONTA into combination regimens and earlier lines of therapy.

Average Trading Volume: 1,188,749

Technical Sentiment Signal: Buy

Current Market Cap: $438.5M

See more data about ADCT stock on TipRanks’ Stock Analysis page.